Paper · 42930173

Cancer Immunotherapy and Immune-Related Adverse Events: Focusing on Non-Small Cell Lung Cancer.

Kamil A and 8 others. Curr Oncol, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Cancer Immunotherapy and Immune-Related Adverse Events: Focusing on Non-Small Cell Lung Cancer. Papers, record 42930173. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42930173

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Cancer Immunotherapy and Immune-Related Adverse Events: Focusing on Non-Small Cell Lung Cancer.
Journal: Curr Oncol
Year: 2026
Publication types: Journal Article, Review
PubMed: https://pubmed.ncbi.nlm.nih.gov/42930173/
DOI: https://doi.org/10.3390/curroncol33100607
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13703719/
The journal: https://conductscience.org/library/journal-index/9502503
Revised in PubMed: 2026-10-29

Source PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Kamil A	Atif	https://orcid.org/0000-0002-0639-9142
2	Cowles S	Sara
3	Driver CC	Casaundra C
4	Arora A	Aakriti
5	Swyers MM	Madison M
6	Boldt LW	Luke W	https://orcid.org/0009-0002-5070-0868
7	Muzaffar M	Mahvish	https://orcid.org/0000-0002-2619-7724
8	Batoo SA	Sameer A
9	Yang LV	Li V	https://orcid.org/0000-0002-8654-4927

Source PubMed

Topics5

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Carcinoma, Non-Small-Cell Lung	Major topic
Immunotherapy	Major topic
Lung Neoplasms	Major topic
Immune Checkpoint Inhibitors	Major topic
Humans

Source PubMed

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Country	NIH project	Stated by	Source
R03 CA249473	NCI NIH HHS	United States	R03CA249473	PubMed	NIH RePORTER
	Lung Cancer Initiative of North Carolina			PubMed	PubMed
5R03CA249473-02	NIH HHS	United States	R03CA249473	PubMed	NIH RePORTER

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References218

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	36,735,893	Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.	J Clin Oncol	2023	https://conductscience.org/library/papers/36735893	PubMed
2	37,852,738	Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer.	J Immunother Cancer	2023	https://conductscience.org/library/papers/37852738	PubMed
3	29,695,768	Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.	Br J Cancer	2018	https://conductscience.org/library/papers/29695768	PubMed
4	34,121,061	Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases.	J Immunother	2021	https://conductscience.org/library/papers/34121061	PubMed
5	31,350,295	The Tumor Microenvironment Innately Modulates Cancer Progression.	Cancer Res	2019	https://conductscience.org/library/papers/31350295	PubMed
6	24,880,949	Immune checkpoint blockade.	Hematol Oncol Clin North Am	2014	https://conductscience.org/library/papers/24880949	PubMed
7	31,031,762	Personalized Dendritic Cell Vaccines-Recent Breakthroughs and Encouraging Clinical Results.	Front Immunol	2019	https://conductscience.org/library/papers/31031762	PubMed
8	21,436,444	Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.	Science	2011	https://conductscience.org/library/papers/21436444	PubMed
9	35,277,447	Pulmonary tuberculosis associated with immune checkpoint inhibitors: a pharmacovigilance study.	Thorax	2022	https://conductscience.org/library/papers/35277447	PubMed
10	22,781,695	Oncolytic virotherapy.	Nat Biotechnol	2012	https://conductscience.org/library/papers/22781695	PubMed

1 to 10 of 218

See all 218 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42930173

GET https://conductscience.org/api/papers/v1/42930173/references?page=2

API reference For AI assistants